世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

治療薬物モニタリング市場:製品毎(消耗品、機器)、技術毎(蛍光免疫測定、放射免疫測定、ガスクロマトグラフィ・質量分析)、薬物クラス毎(抗生物質、気管支拡張薬)、エンドユーザ毎(病院検査室) - 2023年までの世界市場予測

Therapeutic Drug Monitoring Market by Product (Consumable, Equipment (Immunoassay analyzer)), Technology (Fluorescence Immunoassay, Radioimmunoassay, GCMS), Class of drugs (Antibiotics, Bronchodilators), End User (Hospital Lab) - Global Forecast to 2023

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2018年8月US$5,650
シングルユーザライセンス
142 168

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の治療薬物モニタリング市場に関する調査レポートです。

“The global therapeutic drug monitoring market is projected to grow at a CAGR of 5.9%.”

The therapeutic drug monitoring market is expected to reach USD 1.63 billion by 2023 from USD 1.23 billion in 2018, at a CAGR of 5.9% during the forecast period. The growth of this market is majorly driven by the rising number of organ transplant procedures and the use of TDM in traditional anticancer therapies. However, the lack of financial provisions for the clinical interpretation of TDM results is expected to restrain the growth of this market during the forecast period.

“Hospital laboratories are expected to account for the largest share of the therapeutic drug monitoring market in 2018.”

On the basis of end user, the therapeutic drug monitoring market is divided into hospital laboratories, commercial/private laboratories, and other end users. In 2018, the hospital laboratories segment is expected to account for the largest share of the therapeutic drug monitoring market. The large share of this segment is attributed to the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories as they have the appropriate equipment as well as skilled staff to deliver clinically meaningful interpretations from TDM assays. Compared to reference laboratories, hospital laboratories are also more accessible and offer faster results.

“The consumables segment is expected to dominate the market in 2018.”

On the basis of products, the TDM market is segmented into consumables and equipment. In 2018, the consumables segment is expected to account for a larger share of this market owing to the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases.

“The antiepileptic drugs segment is expected to dominate the market in 2018.”

On the basis of class of drugs, the TDM market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive agents, and other drugs. In 2018, the antiepileptic drugs segment is expected to account for the largest share of the market. Antiepileptics are the most commonly monitored class of drugs due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs.

“The immunoassays segment is expected to dominate the market in 2018.”

On the basis of technology, the therapeutic drug monitoring market is classified into immunoassays and chromatography-MS. The immunoassays segment is expected to account for the largest share of this market in 2018, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation.

“North America is expected to account for the largest share of the market in 2018.”

By region, North America is expected to account for the largest share of the TDM market in 2018, followed by Europe. The dominant share of the North American market is primarily due to its well-established pharmaceutical industry, favorable government funding, and high R&D investments in this region.

Break-up profile of primaries:

- By Company Type- Tier 1-33%, Tier 2-40% and Tier 3-27%
- By Designation- C-level-21%, D-level-36% and Others-43%
- By Region- North America-43%, Europe-31%, Asia Pacific-18%, and RoW-8%

The key players operating in the TDM market are F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), and Abbott (US).

Research Coverage:

The therapeutic drug monitoring market in this report is segmented by technology, product, class of drug, and end user. The study tracks and analyzes competitive developments such as product launches, approvals, and acquisitions. It also profiles key players and their core competencies in the therapeutic drug monitoring market.

Reasons to buy this report:

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the portfolios offered by the top players in the therapeutic drug monitoring market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global therapeutic drug monitoring market
- Market Development: Comprehensive information about lucrative emerging markets-the report analyzes markets for therapeutic drug monitoring products across regions
- Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the market
- Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global therapeutic drug monitoring market



目次

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKET COVERED 16
1.3.2 YEARS COVERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17

2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.2 MARKET SIZE ESTIMATION 19
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.3.1 KEY DATA SOURCES FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.2.1 Key industry insights 24

3 EXECUTIVE SUMMARY 25

4 PREMIUM INSIGHTS 28
4.1 THERAPEUTIC DRUG MONITORING (TDM): MARKET OVERVIEW 28
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 29
4.3 GEOGRAPHIC MIX: THERAPEUTIC DRUG MONITORING MARKET 30
4.4 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 30

5 MARKET OVERVIEW 31
5.1 INTRODUCTION 31
5.2 MARKET DYNAMICS 31
5.2.1 DRIVERS 32
5.2.1.1 Use of TDM in traditional anticancer therapies 32
5.2.1.2 Rising number of organ transplant procedures 32
5.2.2 RESTRAINTS 32
5.2.2.1 Reluctance of small hospitals to offer TDM services 32
5.2.3 OPPORTUNITIES 33
5.2.3.1 Monitoring of biosimilars in autoimmune diseases 33
5.2.4 CHALLENGES 33
5.2.4.1 Operational barriers faced in conducting TDM tests 33

6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 34
6.1 INTRODUCTION 35
6.2 CONSUMABLES 35
6.3 EQUIPMENT 37
6.3.1 IMMUNOASSAY ANALYZERS 39
6.3.2 CHROMATOGRAPHY AND MS DETECTORS 40
6.3.3 CLINICAL CHEMISTRY ANALYZERS 40

7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 42
7.1 INTRODUCTION 43
7.2 IMMUNOASSAYS 43
7.2.1 CHEMILUMINESCENT IMMUNOASSAYS 45
7.2.2 FLUORESCENCE IMMUNOASSAYS 47
7.3 COLORIMETRIC IMMUNOASSAYS 48
7.4 RADIOIMMUNOASSAYS 50
7.5 OTHER IMMUNOASSAYS 51
7.6 CHROMATOGRAPHY-MS 53
7.6.1 LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY (LC-MS) 54
7.6.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 56

8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 58
8.1 INTRODUCTION 59
8.2 ANTIEPILEPTIC DRUGS 59
8.3 ANTIARRHYTHMIC DRUGS 61
8.4 IMMUNOSUPPRESSANT DRUGS 63
8.5 ANTIBIOTIC DRUGS 64
8.6 BRONCHODILATOR DRUGS 65
8.7 PSYCHOACTIVE DRUGS 67
8.8 OTHER DRUG CLASSES 68

9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 70
9.1 INTRODUCTION 71
9.2 HOSPITAL LABORATORIES 71
9.3 COMMERCIAL/PRIVATE LABORATORIES 73
9.4 OTHER END USERS 75
-
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION 77
10.1 INTRODUCTION 78
10.2 NORTH AMERICA 78
10.2.1 US 83
10.2.2 CANADA 86
10.3 EUROPE 89
10.4 ASIA PACIFIC 92
10.4.1 JAPAN 97
10.4.2 CHINA 100
10.4.3 INDIA 103
10.4.4 ROAPAC 106
10.5 REST OF THE WORLD 109

11 COMPETITIVE LANDSCAPE 112
11.1 INTRODUCTION 112
11.2 MARKET RANKING ANALYSIS 112
11.3 COMPETITIVE SITUATION AND TRENDS 113
11.3.1 PRODUCT LAUNCHES 113
11.3.2 MERGERS & ACQUISITIONS 113

12 COMPANY PROFILES 114
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 ABBOTT LABORATORIES 114
12.2 F. HOFFMANN-LA ROCHE 116
12.3 SIEMENS HEALTHINEERS 119
12.4 THERMO FISHER SCIENTIFIC 122
12.5 DANAHER CORPORATION 125
12.6 BIO-RAD LABORATORIES 127
12.7 BIOM-RIEUX 129
12.8 B-HLMANN LABORATORIES 131
12.9 SEKISUI MEDICAL 132
12.10 RANDOX LABORATORIES 134

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
-
13 APPENDIX 135
13.1 DISCUSSION GUIDE 135
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 138
13.3 AVAILABLE CUSTOMIZATIONS 140
13.4 RELATED REPORTS 140
13.5 AUTHOR DETAILS 141

 

LIST OF TABLES

TABLE 1 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 35
TABLE 2 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION,
2016-2023 (USD MILLION) 35
TABLE 3 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 36
TABLE 4 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 36
TABLE 5 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION,
2016-2023 (USD MILLION) 37
TABLE 6 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 38
TABLE 7 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 38
TABLE 8 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 38
TABLE 9 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS,
BY REGION, 2016-2023 (USD MILLION) 39
TABLE 10 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY AND MS DETECTORS, BY REGION, 2016-2023 (USD MILLION) 40
TABLE 11 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2016-2023 (USD MILLION) 41
TABLE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 43
TABLE 13 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 44
TABLE 14 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY REGION, 2016-2023 (USD MILLION) 44
TABLE 15 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 44
TABLE 16 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 45
TABLE 17 CLIA SYSTEMS AVAILABLE IN THE MARKET 45
TABLE 18 CHEMILUMINESCENT IMMUNOASSAYS MARKET, BY REGION,
2016-2023 (USD MILLION) 46
TABLE 19 NORTH AMERICA: CHEMILUMINESCENT IMMUNOASSAYS MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 46
TABLE 20 ASIA PACIFIC: CHEMILUMINESCENT IMMUNOASSAYS MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 46
TABLE 21 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION,
2016-2023 (USD MILLION) 47
TABLE 22 NORTH AMERICA: FLUORESCENCE IMMUNOASSAYS MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 47
TABLE 23 ASIA PACIFIC: FLUORESCENCE IMMUNOASSAYS MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 48
TABLE 24 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION,
2016-2023 (USD MILLION) 48
TABLE 25 NORTH AMERICA: COLORIMETRIC IMMUNOASSAYS MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 49
TABLE 26 ASIA PACIFIC: COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 49
TABLE 27 RADIOIMMUNOASSAYS MARKET, BY REGION, 2016-2023 (USD MILLION) 50
TABLE 28 NORTH AMERICA: RADIOIMMUNOASSAYS MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 50
TABLE 29 ASIA PACIFIC: RADIOIMMUNOASSAYS MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 51
TABLE 30 OTHER IMMUNOASSAYS MARKET, BY REGION, 2016-2023 (USD MILLION) 51
TABLE 31 NORTH AMERICA: OTHER IMMUNOASSAYS MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 52
TABLE 32 ASIA PACIFIC: OTHER IMMUNOASSAYS MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 52
TABLE 33 THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 53
TABLE 34 THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET,
BY REGION, 2016-2023 (USD MILLION) 53
TABLE 35 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 54
TABLE 36 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS,
BY COUNTRY, 2016-2023 (USD MILLION) 54
TABLE 37 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET,
BY REGION, 2016-2023 (USD MILLION) 55
TABLE 38 NORTH AMERICA: LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 55
TABLE 39 ASIA PACIFIC: LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 56
TABLE 40 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION,
2016-2023 (USD MILLION) 56
TABLE 41 NORTH AMERICA: GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 57
TABLE 42 ASIA PACIFIC: GC-MS MARKET, BY COUNTRY, 2016-2023 (USD MILLION) 57
TABLE 43 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 59
TABLE 44 GUIDELINES FOR THE MONITORING OF ANTIEPILEPTIC DRUGS 60
TABLE 45 ANTIEPILEPTIC DRUGS MONITORING MARKET, BY REGION,
2016-2023 (USD MILLION) 60
TABLE 46 NORTH AMERICA: ANTIEPILEPTIC DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 60
TABLE 47 ASIA PACIFIC: ANTIEPILEPTIC DRUGS MONITORING MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 61
TABLE 48 ANTIARRHYTHMIC DRUGS MONITORING MARKET, BY REGION,
2016-2023 (USD MILLION) 61
TABLE 49 NORTH AMERICA: ANTIARRHYTHMIC DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 62
TABLE 50 ASIA PACIFIC: ANTIARRHYTHMIC DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 62
TABLE 51 IMMUNOSUPPRESSANT DRUGS MONITORING MARKET, BY REGION,
2016-2023 (USD MILLION) 63
TABLE 52 NORTH AMERICA: IMMUNOSUPPRESSANT DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 63
TABLE 53 ASIA PACIFIC: IMMUNOSUPPRESSANT DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 64
TABLE 54 ANTIBIOTIC DRUGS MONITORING MARKET, BY REGION,
2016-2023 (USD MILLION) 64
TABLE 55 NORTH AMERICA: ANTIBIOTIC DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 65
TABLE 56 ASIA PACIFIC: ANTIBIOTIC DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 65
TABLE 57 THERAPEUTIC RANGES FOR BRONCHODILATORS 65
TABLE 58 BRONCHODILATOR DRUGS MONITORING MARKET, BY REGION,
2016-2023 (USD MILLION) 66
TABLE 59 NORTH AMERICA: BRONCHODILATOR DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 66
TABLE 60 ASIA PACIFIC: BRONCHODILATOR DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 66
TABLE 61 PSYCHOACTIVE DRUGS MONITORING MARKET, BY REGION,
2016-2023 (USD MILLION) 67
TABLE 62 NORTH AMERICA: PSYCHOACTIVE DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 67
TABLE 63 ASIA PACIFIC: PSYCHOACTIVE DRUGS MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 68
TABLE 64 OTHER DRUGS MONITORING MARKET, BY REGION, 2016-2023 (USD MILLION) 68
TABLE 65 NORTH AMERICA: OTHER DRUGS MONITORING MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 69
TABLE 66 ASIA PACIFIC: OTHER DRUGS MONITORING MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 69
TABLE 67 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 71
TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES,
BY REGION, 2016-2023 (USD MILLION) 72
TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING FOR HOSPITAL LABORATORIES, BY COUNTRY, 2016-2023 (USD MILLION) 72
TABLE 70 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING FOR HOSPITAL LABORATORIES, BY COUNTRY, 2016-2023 (USD MILLION) 72
TABLE 71 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL/PRIVATE LABORATORIES, BY REGION, 2013-2023 (USD MILLION) 73
TABLE 72 NORTH AMERICA: THERAPEUTIC DRUG MONITORING FOR COMMERCIAL/ PRIVATE LABORATORIES, BY COUNTRY, 2016-2023 (USD MILLION) 74
TABLE 73 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING FOR COMMERCIAL/ PRIVATE LABORATORIES, BY COUNTRY, 2016-2023 (USD MILLION) 74
TABLE 74 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS,
BY REGION, 2016-2023 (USD MILLION) 75
TABLE 75 NORTH AMERICA: THERAPEUTIC DRUG MONITORING FOR OTHER END USERS,
BY COUNTRY, 2016-2023 (USD MILLION) 75
TABLE 76 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING FOR OTHER END USERS,
BY COUNTRY, 2016-2023 (USD MILLION) 76
TABLE 77 THERAPEUTIC DRUG MONITORING MARKET, BY REGION,
2016-2023 (USD MILLION) 78
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY COUNTRY, 2016-2023 (USD MILLION) 80
TABLE 79 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY PRODUCT, 2016-2023 (USD MILLION) 80
TABLE 80 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2016-2023 (USD MILLION) 80
TABLE 81 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY TECHNOLOGY, 2016-2023 (USD MILLION) 81
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 81
TABLE 83 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 2016-2023 (USD MILLION) 81
TABLE 84 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY CLASS OF DRUG, 2016-2023 (USD MILLION) 82
TABLE 85 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET,
BY END USER, 2016-2023 (USD MILLION) 82
TABLE 86 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 83
TABLE 87 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 84
TABLE 88 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 84
TABLE 89 US: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 84
TABLE 90 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 85
TABLE 91 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 85
TABLE 92 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 86
TABLE 93 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 87
TABLE 94 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 87
TABLE 95 CANADA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 2016-2023 (USD MILLION) 87
TABLE 96 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 88
TABLE 97 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 88
TABLE 98 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 89
TABLE 99 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2016-2023 (USD MILLION) 90
TABLE 100 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 90
TABLE 101 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 90
TABLE 102 EUROPE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 2016-2023 (USD MILLION) 91
TABLE 103 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 91
TABLE 104 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 92
TABLE 105 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY,
2016-2023 (USD MILLION) 94
TABLE 106 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 94
TABLE 107 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2016-2023 (USD MILLION) 94
TABLE 108 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION) 95
TABLE 109 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 95
TABLE 110 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 2016-2023 (USD MILLION) 95
TABLE 111 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016-2023 (USD MILLION) 96
TABLE 112 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 96
TABLE 113 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 97
TABLE 114 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 97
TABLE 115 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 98
TABLE 116 JAPAN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 98
TABLE 117 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 99
TABLE 118 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 99
TABLE 119 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 100
TABLE 120 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 100
TABLE 121 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 101
TABLE 122 CHINA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 101
TABLE 123 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 102
TABLE 124 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 102
TABLE 125 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 103
TABLE 126 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 103
TABLE 127 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 104
TABLE 128 INDIA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 104
TABLE 129 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 105
TABLE 130 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 105
TABLE 131 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 106
TABLE 132 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 106
TABLE 133 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 107
TABLE 134 ROAPAC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 2016-2023 (USD MILLION) 107
TABLE 135 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 108
TABLE 136 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 108
TABLE 137 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016-2023 (USD MILLION) 109
TABLE 138 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2016-2023 (USD MILLION) 109
TABLE 139 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016-2023 (USD MILLION) 110
TABLE 140 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 110
TABLE 141 ROW: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET,
BY TYPE, 2016-2023 (USD MILLION) 110
TABLE 142 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016-2023 (USD MILLION) 111
TABLE 143 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016-2023 (USD MILLION) 111
TABLE 144 PRODUCT LAUNCHES/APPROVALS, 2015-2018 113
TABLE 145 MERGERS & ACQUISITIONS, 2015-2018 113

 

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 18
FIGURE 2 THERAPEUTIC DRUG MONITORING MARKET: TOP-DOWN APPROACH 20
FIGURE 3 THERAPEUTIC DRUG MONITORING MARKET: BOTTOM-UP APPROACH 20
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 21
FIGURE 5 DATA TRIANGULATION METHOD 22
FIGURE 6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2018 VS. 2023 (USD BILLION) 25
FIGURE 7 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2018 VS. 2023 (USD MILLION) 26
FIGURE 8 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2018 VS. 2023 (USD MILLION) 26
FIGURE 9 GEOGRAPHIC SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET 27
FIGURE 10 GROWTH OF THIS MARKET IS MAJORLY DRIVEN BY THE RISING NUMBER OF ORGAN TRANSPLANT PROCEDURES 28
FIGURE 11 ANTIEPILEPTIC DRUGS WILL DOMINATE THE ASIA PACIFIC TDM CLASS OF DRUGS MARKET IN 2018 29
FIGURE 12 APAC TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD 30
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 31
FIGURE 14 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT 79
FIGURE 15 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT 93
FIGURE 16 THERAPEUTIC DRUG MONITORING MARKET RANKING ANALYSIS,
BY KEY PLAYER, 2017 112
FIGURE 17 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2017) 114
FIGURE 18 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017) 116
FIGURE 19 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2017) 119
FIGURE 20 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017) 122
FIGURE 21 DANAHER CORPORATION: COMPANY SNAPSHOT (2017) 125
FIGURE 22 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2017) 127
FIGURE 23 BIOM-RIEUX: COMPANY SNAPSHOT (2017) 129

 

ページTOPに戻る

プレスリリース

[プレスリリース原文]

Therapeutic Drug Monitoring Market worth $1.63 billion in 2023


August 22, 2018

The report "Therapeutic Drug Monitoring Market by Product (Consumable, Equipment (Immunoassay analyzer)), Technology (Fluorescence Immunoassay, Radioimmunoassay, GCMS), Class of drugs (Antibiotics, Bronchodilators), End User (Hospital Lab) - Global Forecast to 2023", The global therapeutic drug monitoring market is projected to reach USD 1.63 billion in 2023 from USD 1.23 billion in 2018, at a CAGR of 5.9%. The growth of this market is majorly driven by the rising number of organ transplant procedures and the use of TDM in traditional anticancer therapies.

Based on product, the consumables segment is expected to grow at the highest CAGR during the forecast period

On the basis of product, the global therapeutic drug monitoring market is segmented into consumables and equipment. The consumables segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases.

Based on technology, the immunoassays segment is expected to account for the largest share of the market in 2018

On the basis of technology, the global therapeutic drug monitoring market is segmented into immunoassays and chromatography-MS. The immunoassays segment is expected to account for the largest share of this market in 2018, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation.

Asia Pacific is expected to grow at the highest CAGR during the forecast period

The APAC market is projected to register the highest growth during the forecast period. Growth in this region can be attributed to the huge demand for better healthcare services; increasing incidence of chronic and infectious diseases; rapid development in healthcare infrastructure in developing countries such as India, China, and South Korea; growing healthcare research investments in this region; and increasing per capita income of the middle-class population.

Market Players

The key players operating in the TDM market are F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), and Abbott (US).

 

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る